Tempus AI

Tempus AI is an American health technology company founded in 2015 by Eric Lefkofsky in Chicago, Illinois. It was established by Eric soon after his wife was diagnosed with breast cancer. Tempus uses data and artificial intelligence to create precision medicine solutions, including diagnostics, for oncology, cardiology, and depression. The company went public on June 14, 2024 under the ticker symbol "TEM."

Business Tempus is headquartered in Chicago, with offices in New York and San Francisco. It has three CAP/CLIA labs in Chicago, Atlanta, and Research Triangle Park. Tempus does next-generation sequencing primarily for cancer patients, and pharmacogenomic testing for patients with depression.

Tempus investors include Baillie Gifford, New Enterprise Associates, Novo Holdings, Franklin Templeton Investments, Revolution LLC, Google LLC, etc.